Content area

|
|

Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase

Forfatter(e)
Kristian S. Frederiksen1, Steen Hasselbalch1, Ian Law2, Liselotte Højgaard2 & Gunhild Waldemar1 1) Nationalt Videnscenter for Demens, Neurologisk Klinik, Neurocentret, Rigshospitalet 2) Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Rigshospitalet Ugeskr Læger 2015;177:V12140684
Reference: 
Ugeskr Læger 2015;177:V12140684
Blad nummer: 
Sidetal: 
1518-1521
Biomarkers for early diagnosis of Alzheimer’s disease
Alzheimer’s disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Per Bennicke | 19/10
1 Kommentar
af Sven Refslund Poulsen | 16/10
1 Kommentar
af Jens Ole Mathiesen | 16/10
1 Kommentar
af Gunnar Lauge Nielsen | 13/10
1 Kommentar
af Morten Krogh Jensen | 13/10
11 kommentarer
af Frank Østergaard Hansen | 12/10
1 Kommentar
af Debatred. | 12/10
1 Kommentar